In one sentence
A Turkish clinic study of 50 autistic children found higher activity in several inflammation-related genes than in unrelated healthy controls, and those gene signals correlated with language, sensory, and motor scores — useful as research context, not as a home inflammation test.
What the researchers did
The team measured expression of genes in two pathways often discussed in neuroinflammation: NLRP3 inflammasome-related genes and the RANK–RANKL–OPG pathway. They compared 50 autistic children aged 3–18 with 34 typically developing siblings and 16 unrelated healthy controls. Autistic participants were also scored with tools covering autism severity (CARS), communication, sensory profiles, and neuromotor performance. Researchers then checked whether gene expression lined up with those clinical scores.
What they found
All seven measured genes showed higher average expression in the autism group, but only three RANK–RANKL–OPG pathway genes (TNFRSF11B, TNFRSF11A, and TNFSF11) differed significantly from unrelated healthy controls. Expression levels correlated with linguistic and cognitive skills, sensory profile scores, and neuromotor performance. Sibling comparisons were included to help separate shared family background from autism-associated patterns, though sibling groups are not a perfect control.
What this means for families and therapists
This adds to a larger research story that immune and inflammatory signalling sometimes look different in autistic samples. It does not show that autism is “caused by inflammation,” that blood gene panels diagnose autism, or that anti-inflammatory supplements or drugs are proven treatments.
For therapists, the practical link is indirect: sensory and motor profiles already matter in daily support, and biological research is beginning to study the same domains. Stay sceptical of clinics selling unproven “inflammation protocols.” Discuss any lab interest with a paediatrician who knows the child’s full medical picture. Related reading: our digests on gut microbiota and neurodevelopment and fecal inflammatory markers.
Limitations and what we don't know yet
The autism sample was modest (n = 50) and from one setting. The design is cross-sectional, so direction of effect is unknown. License metadata for the source is incomplete in our ingest, so we summarise loosely rather than quoting tightly. Gene expression is not the same as protein levels or clinical inflammation markers. Replication in larger, multi-site cohorts is needed before any clinical use.
This is a plain-language summary of NLRP3 and RANK-RANKL-OPG Pathway-related Gene Expression Levels in Children With Autism Spectrum Disorder by Kara B, Savaş M, Özer T et al., In Vivo (2026). Source license: unknown. It is not medical advice — talk to a qualified clinician before changing therapy.